PCM
PCRX icon

Portolan Capital Management’s Pacira BioSciences PCRX Stock Holding History

Portolan Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-131,901
Closed -$3.77M – 144
2024
Q2 		$3.77M Buy
+131,901
New +$3.75M 0.31% 99
2023
Q3 		– Sell
-200,504
Closed -$8.03M – 139
2023
Q2 		$8.03M Buy
+200,504
New +$8.29M 0.71% 40

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Portolan Capital Management's PCRX Position: Q3 2024 in Review

Portolan Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 131,901 shares — an estimated $3.77M sold.

Portolan Capital Management first reported a position in PCRX in Q2 2023 and held it in 2 quarters. The position peaked at $8.03M in Q2 2023. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Portolan Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Portolan Capital Management sold 131,901 Pacira BioSciences shares in Q3 2024, an estimated $3.77M.
  • Portolan Capital Management first reported a position in Pacira BioSciences in Q2 2023 and held it in 2 quarters.
  • Portolan Capital Management's Pacira BioSciences position peaked at $8.03M in Q2 2023.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Portolan Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.